Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2011/051647external-prioritypatent/WO2012032334A1/en
Application filed by Ucb Pharma SafiledCriticalUcb Pharma Sa
Publication of TN2013000080A1publicationCriticalpatent/TN2013000080A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
A series of quinoline and quinoxaline derivatives comprising a fluorinated ethyl side-chain, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
TNP2013000080A2011-09-022013-02-28Quinoline and quinoxaline derivalives as kinase inhibitors
TN2013000080A1
(en)